In that study, the COVID-19-related mortality in T2DM was significantly lower in patients prescribed metformin, SGLT2 inhibitors, and SU and higher in patients prescribed DPP-4 inhibitors and insulin vs. those not prescribed these medications (12). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.